Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

VistaGen Therapeutics

VistaGen Therapeutics
1998 FOUNDED
PUBLIC STATUS
1-10 EMPLOYEES
VTGN STOCK SYMBOL
1 INVESTMENTS
$1.04 SHARE PRICE (As of Friday Closing)
Description

VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants.

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 343 Allerton Avenue
  • South San Francisco, CA 94080
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore VistaGen Therapeutics’s full profile, request a free trial.

VistaGen Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.38 - $2.44 $44.3M $1.10 -$0.84 270K 42.6M

VistaGen Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2019
31-Mar-2019
FY 2018
31-Mar-2018
FY 2017
31-Mar-2017
Enterprise Value 17,893 46,412 8,280 13,972
Revenue 0 0 0 1,250
EBITDA (26,491) (24,488) (14,254) (10,194)
Net Income (26,585) (24,590) (14,346) (10,256)
Total Assets 12,947 14,012 11,278 3,712
Total Debt 4,490 67 66 69
Public Fundamental Data provided by Morningstar, Inc. disclaimer

VistaGen Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore VistaGen Therapeutics‘s full profile, request access.

Request full access to PitchBook

VistaGen Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000000 11-May-2011 000000000000000000 Other Consumer Products and Services 00000 00000 00
To view this company’s complete investment and acquisition history, request access »

VistaGen Therapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore VistaGen Therapeutics‘s full profile, request access.

Request full access to PitchBook

VistaGen Therapeutics Executive Team (7)

Name Title Board
Seat
Contact
Info
Shawn Singh JD Chief Executive Officer & Board Member
Ralph Snodgrass Director, President & Chief Scientific Officer & Co-Founder
Jerrold Dotson Chief Financial Officer & Chief Accounting Officer
Gordon Keller Co-Founder
Mark McPartland Vice President
You’re viewing 5 of 7 executives. Get the full list »

VistaGen Therapeutics Board Members (3)

Name Representing Role Since Contact
Info
00000 000000000 00.0 VistaGen Therapeutics Director 000 0000
0000 0000 00 Self Chairman 000 0000
00000 00000 00 VistaGen Therapeutics Chief Executive Officer & Board Member 000 0000